You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,365,500


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,365,500
Title:9-aminomethyl substituted minocycline compounds
Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Inventor(s): Nelson; Mark L. (Norfolk, MA), Frechette; Roger (Reading, MA), Ismail; Mohamed Y. (Bedford, MA), Honeyman; Laura (Etobicoke, CA), Bowser; Todd (Charlton, MA), Bhatia; Beena (Mansfield, MA)
Assignee: PARATEK PHARMACEUTICALS, INC. (Boston, MA)
Application Number:14/318,031
Patent Claims: 1. A method for treating a bacterial infection in a subject, comprising administering to said subject a compound having the following structure: ##STR00044## or a pharmaceutically acceptable salt or ester thereof.

2. The method of claim 1, wherein said bacterial infection is associated with gram positive bacteria.

3. The method of claim 1, wherein said bacterial infection is associated with gram negative bacteria.

4. The method of claim 1, wherein said bacterial infection is associated with E. coli.

5. The method of claim 1, wherein said bacterial infection is associated with S. aureus.

6. The method of claim 1, wherein said bacterial infection is associated with E. faecalis.

7. The method of claim 1, wherein said bacterial infection is resistant to other tetracycline antibiotics.

8. The method of claim 1, wherein said compound is administered with a pharmaceutically acceptable carrier.

9. The method of claim 1, wherein said subject is a mammal.

10. The method of claim 1, wherein said subject is a human.

11. A method for treating a bacterial infection in a subject, comprising administering to said subject a compound having the following structure: ##STR00045## or a pharmaceutically acceptable salt thereof.

12. The method of claim 11, wherein said bacterial infection is associated with gram positive bacteria.

13. The method of claim 11, wherein said bacterial infection is associated with gram negative bacteria.

14. The method of claim 11, wherein said bacterial infection is associated with E. coli.

15. The method of claim 11, wherein said bacterial infection is associated with S. aureus.

16. The method of claim 11, wherein said bacterial infection is associated with E. faecalis.

17. The method of claim 11, wherein said bacterial infection is resistant to other tetracycline antibiotics.

18. The method of claim 11, wherein said compound is administered with a pharmaceutically acceptable carrier.

19. The method of claim 11, wherein said subject is a mammal.

20. The method of claim 11, wherein said subject is a human.

21. A method for treating a bacterial infection in a subject, comprising administering to said subject a pharmaceutically acceptable salt of the compound having the following structure: ##STR00046##

22. The method of claim 21, wherein said bacterial infection is associated with gram positive bacteria.

23. The method of claim 21, wherein said bacterial infection is associated with gram negative bacteria.

24. The method of claim 21, wherein said bacterial infection is associated with E. coli.

25. The method of claim 21, wherein said bacterial infection is associated with S. aureus.

26. The method of claim 21, wherein said bacterial infection is associated with E. faecalis.

27. The method of claim 21, wherein said bacterial infection is resistant to other tetracycline antibiotics.

28. The method of claim 21, wherein said compound is administered with a pharmaceutically acceptable carrier.

29. The method of claim 21, wherein said subject is a mammal.

30. The method of claim 21, wherein said subject is a human.

31. The method of claim 1, wherein said bacterial infection is associated with K. pneumoniae.

32. The method of claim 1, wherein said bacterial infection is associated with Salmonella.

33. The method of claim 1, wherein said bacterial infection is associated with E. hirae.

34. The method of claim 1, wherein said bacterial infection is associated with A. baumanii.

35. The method of claim 1, wherein said bacterial infection is associated with B. catarrhalis.

36. The method of claim 1, wherein said bacterial infection is associated with H. influenzae.

37. The method of claim 1, wherein said bacterial infection is associated with P. aeruginosa.

38. The method of claim 1, wherein said bacterial infection is associated with E. faecium.

39. The method of claim 11, wherein said bacterial infection is associated with K. pneumoniae.

40. The method of claim 11, wherein said bacterial infection is associated with Salmonella.

41. The method of claim 11, wherein said bacterial infection is associated with E. hirae.

42. The method of claim 11, wherein said bacterial infection is associated with A. baumanii.

43. The method of claim 11, wherein said bacterial infection is associated with B. catarrhalis.

44. The method of claim 11, wherein said bacterial infection is associated with H. influenzae.

45. The method of claim 11, wherein said bacterial infection is associated with P. aeruginosa.

46. The method of claim 21, wherein said bacterial infection is associated with E. faecium.

47. The method of claim 21, wherein said bacterial infection is associated with K. pneumoniae.

48. The method of claim 21, wherein said bacterial infection is associated with Salmonella.

49. The method of claim 21, wherein said bacterial infection is associated with E. hirae.

50. The method of claim 21, wherein said bacterial infection is associated with A. baumanii.

51. The method of claim 21, wherein said bacterial infection is associated with B. catarrhalis.

52. The method of claim 21, wherein said bacterial infection is associated with H. influenzae.

53. The method of claim 21, wherein said bacterial infection is associated with P. aeruginosa.

54. The method of claim 21, wherein said bacterial infection is associated with E. faecium.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.